Xenome in third screening partnership

By Pete Young
Wednesday, 27 March, 2002


Brisbane biotech and animal venom specialist Xenome Ltd has found yet another partner to screen its library of bioactive peptide molecules.

Its latest agreement, the third signed in less than a month, is with Icagen Inc, a private US company focused on ion channel therapeutics.

Xenome molecules based on structures isolated from venomous species will be screened against the North Carolina company's proprietary ion channel drug targets.

The new partnership is broader in scope than an earlier agreement Xenome negotiated with another ion channel specialist, UK-based Ionix Pharmaceuticals.

Channels regulating the flow of ions in cells are crucial to the development of many diseases.

Xenome has also struck an agreement to test its molecules against Melbourne-based Cytopia Ltd's anti-inflammatory and anti-cancer targets.

The latest collaboration, like the others, will see the partners sharing equally in any IP and commercial rewards which flow from the joint venture.

The various agreements contain exclusive and non-exclusive clauses which have been structured to avoid any conflicts of interest, according to Xenome CEO Tony Evans.

Related News

Brainwaves can predict future pain sensitivity

Scientists have demonstrated that one particularly prevalent pattern of brain activity, called...

REM sleep regulates eating behaviour

Electrical activity in hypothalamic circuits during REM sleep is essential to maintain a stable...

High BMI negatively impacts brain function

Being overweight or obese seriously impacts brain activity and increases the risk for...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd